F-star Therapeutics Inc.

8.40+0.3000+3.70%Vol 145.47K1Y Perf 29.35%
Jun 16th, 2021 16:00 DELAYED
BID6.80 ASK9.00
Open8.09 Previous Close8.10
Pre-Market- After-Market-
 - -  - -%
Target Price
30.00 
Analyst Rating
— — 0.00
Potential %
257.14 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+ —    38.29
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap162.67M 
Earnings Rating
Price Range Ratio 52W %
38.90 
Earnings Date
9th Aug 2021

Today's Price Range

8.098.45

52W Range

3.8815.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
16.83%
1 Month
21.21%
3 Months
-24.93%
6 Months
-9.48%
1 Year
29.35%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FSTX8.400.30003.70
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Earnings HistoryEstimateReportedSurprise %
Q01 2021-1.26-1.0814.29
Q02 2020-1.44-1.52-5.56
Q01 2020-0.80-1.96-145.00
Q04 2019-1.96-1.808.16
Q03 2019-2.48-1.6832.26
Q02 2019-2.24-1.1250.00
Q01 2019-0.54-0.499.26
Q04 2018-0.50-0.3334.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.80
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume145.47K
Shares Outstanding19.37M
Trades Count1.45K
Dollar Volume341.60K
Avg. Volume145.87K
Avg. Weekly Volume158.40K
Avg. Monthly Volume203.75K
Avg. Quarterly Volume215.70K

F-star Therapeutics Inc. (NASDAQ: FSTX) stock closed at 9.32 per share at the end of the most recent trading day (a 3.7% change compared to the prior day closing price) with a volume of 520.98K shares and market capitalization of 162.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 79 people. F-star Therapeutics Inc. CEO is Eliot Richard Forster.

The one-year performance of F-star Therapeutics Inc. stock is 29.35%, while year-to-date (YTD) performance is -14.89%. FSTX stock has a five-year performance of %. Its 52-week range is between 3.88 and 15.5, which gives FSTX stock a 52-week price range ratio of 38.90%

F-star Therapeutics Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 4.00, a price-to-sale (PS) ratio of 12.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.01%, a ROC of -72.28% and a ROE of -81.31%. The company’s profit margin is -%, its EBITDA margin is -209.30%, and its revenue ttm is $12.82 Million , which makes it $0.66 revenue per share.

Of the last four earnings reports from F-star Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.80 for the next earnings report. F-star Therapeutics Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for F-star Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for F-star Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

F-star Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

F-star Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 21.57, ATR14 : 0.55, CCI20 : 135.54, Chaikin Money Flow : -0.11, MACD : -0.13, Money Flow Index : 69.04, ROC : 12.90, RSI : 60.44, STOCH (14,3) : 97.30, STOCH RSI : 1.00, UO : 57.93, Williams %R : -2.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of F-star Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

F-star Therapeutics Inc.

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

CEO: Eliot Richard Forster

Telephone: +44 1223497400

Address: Babraham Research Campus, Cambridge CB22 3AT, , GB

Number of employees: 79

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

67%33%

Bearish Bullish

40%60%

Bearish Bullish

50%50%

News

Stocktwits